Farnesyltransferase inhibitors have recently shown clinical efficacy against leukemias,
gliomas and even non-small-cell lung cancers, especially when administered in
combination with taxanes. It is possible that the critical target downstream of
farnesyltransferase responsible for these effects is not either Ras or RhoB, the two most
cited possibilities—but the hunt is on.